SimonMed First Colony TX is a Texas-based medical technology company focused on developing implantable neuromodulation devices to treat chronic pain and neurological conditions. The company operates under the First Colony Innovation Campus in Austin, using local biotech infrastructure and clinical partnerships.
The core product is a minimally invasive, rechargeable implantable pulse generator designed to deliver targeted electrical stimulation to peripheral nerves or spinal cord regions. This system aims to reduce reliance on opioid medications and improve quality of life for patients with refractory neuropathic pain. The device is currently in late-stage clinical trials, with FDA pre-submission feedback received in 2023.
SimonMed First Colony TX was founded in 2018 by Dr. Elena Torres, a former neurosurgeon at MD Anderson Cancer Center, and engineer Rajiv Mehta. The team includes former Medtronic and Boston Scientific R&D leads. The company's research is supported by a $12 million grant from the National Institute of Neurological Disorders and Stroke (NINDS), awarded in 2021 for long-term efficacy studies.
SimonMed's device uses a closed-loop algorithm that adjusts stimulation intensity in real time based on neural feedback collected via microelectrodes embedded in the lead. Unlike older systems that deliver constant pulses, this adaptive modulation reduces energy consumption and improves symptom control.
Implantation takes approximately 60 minutes under local anesthesia. A small incision near the lower back or limb allows placement of the lead along the target nerve. The pulse generator, about the size of a large coin, is implanted beneath the skin in the abdominal wall. Patients use a handheld programmer to adjust settings during follow-up visits.
A 2023 pilot study involving 42 patients with post-surgical neuropathic pain showed a 68% reduction in average pain scores (measured by the Numeric Rating Scale) after six months. Adverse events were limited to minor infection (3%) and lead migration (2%). These results were presented at the American Society of Pain Management meeting in October 2023.
The device consists of three primary elements: the implantable pulse generator (IPG), the percutaneous lead, and the external programmer. The IPG contains a lithium-ion battery with a projected lifespan of 8 years under typical use. It supports wireless charging via a proprietary induction pad worn over the abdomen.
Materials include titanium casing and silicone insulation, both approved by ISO 13485 standards for implantable devices. The device is MRI-compatible up to 1.5 Tesla, a feature lacking in many competing systems. This compatibility reduces patient anxiety and avoids costly imaging delays.
| Component | Function | Regulatory Status |
|---|---|---|
| Implantable Pulse Generator (IPG) | Delivers adjustable electrical pulses to target nerves | Premarket Approval (PMA) application submitted, 2024 |
| Percutaneous Lead | Transmits signals from IPG to neural tissue | 510(k) cleared, 2022 |
| External Programmer | Allows clinicians and patients to adjust settings remotely | Class II device, FDA-cleared |
One non-obvious fact: SimonMed's system uses a novel electrode range design with 16 contact points arranged in a helical pattern. This configuration increases signal precision and reduces cross-talk between adjacent nerves-a problem that plagues traditional linear arrays. The design was validated using computational modeling and cadaver testing at the University of Texas Southwestern Medical Center.
SimonMed First Colony TX targets patients with chronic pain unresponsive to conservative treatments. Common indications include complex regional pain syndrome (CRPS), failed back surgery syndrome (FBSS), and diabetic peripheral neuropathy. The company focuses on patients aged 30-65 who have failed at least three prior therapies, including medication and physical therapy.
Clinical sites include Baylor Scott & White Health, UT Health San Antonio, and Memorial Hermann in Houston. As of Q1 2024, 147 patients have been enrolled across 12 trial centers. The company plans to expand into rural Texas through telehealth-enabled remote monitoring, addressing access gaps in underserved areas.
A notable distinction: unlike many startups that focus on spinal cord stimulation, SimonMed prioritizes peripheral nerve targeting. This shift reduces surgical risk and improves outcomes for limb-specific pain. A 2022 retrospective analysis from Johns Hopkins found that peripheral nerve stimulation had a 22% higher success rate than spinal stimulation for patients with localized neuropathy.
Some assume SimonMed First Colony TX is a public company. It is not. The company remains privately held, with funding from venture capital firms including Flagship Pioneering and Texas Health Innovation Fund. No IPO is planned before 2026.
Another misconception: the device is not intended for acute pain. It requires a minimum of six months of chronic symptoms to qualify. The company's inclusion criteria mandate at least 12 months of documented pain history and failure of at least three standard treatments.
There is also confusion about the difference between "First Colony" and "SimonMed." "First Colony" refers to the Austin-based innovation campus housing the company's R&D and manufacturing facilities. "SimonMed" is the brand name for the medical device portfolio. The campus hosts multiple health-tech ventures under the First Colony umbrella, but only SimonMed develops implantable neuromodulation systems.
Consider Maria Lopez, a 54-year-old nurse from San Marcos, Texas. She developed CRPS in her left foot after a fall in 2020. Despite gabapentin, physical therapy, and two nerve blocks, her pain score remained at 8/10. After enrolling in SimonMed's Phase III trial, she underwent implantation in March 2023.
Three months post-implant, Maria reported a drop to 3/10. Her sleep improved, and she returned to part-time work. At 18 months, she reduced her opioid dose by 70%. Her device has operated continuously since, with no complications. She now participates in patient advocacy groups and speaks at local clinics about living with chronic pain.
Her case illustrates the real-world impact of targeted neuromodulation. The device did not eliminate pain entirely, but it restored function and autonomy-key goals in chronic disease management.
For context, the FDA has granted Breakthrough Device designation to SimonMed's system, accelerating review timelines. This status reflects evidence of substantial improvement over existing therapies. The company expects final approval by late 2025.